Who makes Seysara Oral Product?

Seysara Oral Product is developed by The Dermatology Institute of Boston.

What development phase is Seysara Oral Product in?

Seysara Oral Product is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Seysara Oral Product

The Dermatology Institute of Boston · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	Seysara Oral Product
Sponsor	The Dermatology Institute of Boston
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Sarecycline for Treating Periorificial Dermatitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Seysara Oral Product CI brief — competitive landscape report
Seysara Oral Product updates RSS · CI watch RSS
The Dermatology Institute of Boston portfolio CI